Elai Davicioni: Predicting Dose-Response to Prostate Cancer Radiotherapy
Elai Davicioni, Medical Director of Urology at Veracyte, posted on X about recent paper by A. Dal Pra et al., titled “Predicting Dose-Response to Prostate Cancer Radiotherapy: Validation of a Radiation Signature in the Randomized Phase III NRG/RTOG 0126 and SAKK 09/10 Trials” published on ESMO Annals of Oncology.
Authors: A. Dal Pra, P. Ghadjar, H.M. Ryu, J.A. Proudfoot, S. Hayoz, J.M. Michalski, D.E. Spratt, Y. Liu, C. Schär, A.M. Berlin, Daniel R. Zwahlen, Jeffry P. Simko, T. Hölscher, J.A. Efstathiou, B. Polat, H.M. Sandler, G. Hildebrandt, M.B. Parliament, A.-C. Mueller, I.S. Dayes, L. Plasswilm, R.J.M. Correa, J.M. Robertson, T.G. Karrison, E. Davicioni, W.A. Hall, F.Y. Feng, A. Pollack, G.N. Thalmann, P.L. Nguyen, D.M. Aebersold, P.T. Tran, S.G. Zhao.
“Predicting Dose-Response to Prostate Cancer Radiotherapy: Validation of a Radiation Signature in the Randomized Phase III NRG/RTOG 0126 and SAKK 09/10 Trials – Annals of Oncology.”
Melvin LK Chua, Clinician-Scientist at the NCCS and Duke-NUS Medical School, shared this post on X, adding:
“Congrats on this important work Elai Davicioni!
From our early work to predict DM in IGRT treated patients to now predicting RT dose response – We may have a biomarker for precision radiotherapy in prostate cancer!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023